BridgeMD
New treatment option for Advanced Cancers
Official title Plasmodium Immunotherapy for Advanced Cancers
ClinicalTrials.gov ID: NCT03375983
What this study is testing
What is Blood-stage infection of P.vivax?
Blood-stage infection of P.vivax is an investigational medicine, being studied as a potential treatment for advanced cancers.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- 18-70 years of age, male or female.
- Patients with advanced cancer confirmed by histopathology and imaging; and imaging lesions of the tumor are clear and measurable, including but not...
- The time interval of the termination of chemotherapy (including treatment chemotherapy) or radiotherapy is at least 3 months for patients who had...
- All the patients who have not received surgery, radiotherapy, chemotherapy or targeted drug therapy and refuse to accept the above treatments must...
- ECGO score of 0 or 1;
You likely can't join if
- Patients with severe hemoglobin disease or severe G6PD deficiency;
- Patients with splenectomy or splenomegaly;
- Patients with drug addiction or alcohol dependence;
- With the following diseases or conditions: newly diagnosed with CNS metastasis ( excluding that the tumor lesions of the CNS has disappeared after...
- Accept any other anti-tumor treatment at the same time;
- Patients with significantly lower immune function than those in the normal population;
See the full eligibility criteria
- 18-70 years of age, male or female.
- Patients with advanced cancer confirmed by histopathology and imaging; and imaging lesions of the tumor are clear and measurable, including but not limited to colon cancer, breast cancer, liver cancer, lung cancer...
- The time interval of the termination of chemotherapy (including treatment chemotherapy) or radiotherapy is at least 3 months for patients who had received chemotherapy (including treatment chemotherapy) or radiotherapy...
- All the patients who have not received surgery, radiotherapy, chemotherapy or targeted drug therapy and refuse to accept the above treatments must meet all the remaining requirements that listed in the ;
- ECGO score of 0 or 1;
- Expected survival ≥ 6 months;
- PLT ≥100× 10\^9/L, NE ≥ 1.5 × 10\^9/L, and HGB ≥ 100 g/L; no significant morphological abnormalities of red blood cells, or anemia (iron deficiency anemia, autoimmune hemolytic anemia, thalassemia, etc.);
- The peripheral blood count of immune cells is close to normal or normal, the immune function test result is close to or at the level of normal population, and the function of heart, lung, liver and kidney are basically...
- Patient compliance meets the need for follow-up;
- The people are able to understand and sign informed consent.
- Patients with severe hemoglobin disease or severe G6PD deficiency;
- Patients with splenectomy or splenomegaly;
- Patients with drug addiction or alcohol dependence;
- With the following diseases or conditions: newly diagnosed with CNS metastasis ( excluding that the tumor lesions of the CNS has disappeared after treatment) and serious or uncontrolled systemic disease or any unstable...
- Accept any other anti-tumor treatment at the same time;
- Patients with significantly lower immune function than those in the normal population;
- Lung function is seriously damaged, the MNW \<39% or can't get out of bed, still feel short of breath when resting;
- Rough cough, dyspnea, without normal diet or difficult to cooperate;
- Poor body condition, the researchers assess that the patients can't tolerate the immune therapy;
- Pregnant or lactating women;
- Women of childbearing age with positive result for pregnancy tests;
- Any condition that makes the subject ineligible to participate (in the opinion of the investigator).
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.